

Acta Medica Okayama

Volume 47, Issue 3

1993

Article 5

JUNE 1993

Hyperthermotherapy added to the multidisciplinary therapy for penile cancer.

Masahiro Kuroda, *Okayama University*
Tomoyasu Tsushima, *Okayama University*
Yasutomo Nasu, *Okayama University*
Junichi Asaumi, *Okayama University*
Koji Nishikawa, *Okayama University*
Xian Shu Gao, *Okayama University*
Ikuo Joja, *Okayama University*
Yoshihiro Takeda, *Okayama University*
Izumi Togami, *Okayama University*
Eiichi Makihata, *Okayama University*
Shoji Kawasaki, *Okayama University*
Hiroyuki Ohmori, *Okayama University*
Yoshio Hiraki, *Okayama University*

Hyperthermotherapy added to the multidisciplinary therapy for penile cancer.*

Masahiro Kuroda, Tomoyasu Tsushima, Yasutomo Nasu, Junichi Asaumi, Koji Nishikawa, Xian Shu Gao, Ikuo Joja, Yoshihiro Takeda, Izumi Togami, Eiichi Makihata, Shoji Kawasaki, Hiroyuki Ohmori, and Yoshio Hiraki

Abstract

We performed a long-term follow-up of 4 patients with penile cancer who underwent hyperthermotherapy from August 1985 until August 1992. Hyperthermia was applied using a frequency of 350 MHz with a waveguide applicator twice a week for 60 min each for an average of 9.5 times (varying from 6 to 13 times). The total heating time that the temperature of urethra could be kept above 42 degrees C, was 166 min on the average (ranging from 0 to 463 min). Two patients classified as stage I according to the Jackson classification and 1 patient classified as stage IV underwent combined radiotherapy and received an average radiation dose of 53 Gy (range, 40-70 Gy). Among these patients 2 underwent combined chemotherapy with bleomycin or peplomycin. Malignant cells disappeared posttherapeutically and in August 1992, after an average of 5 years and 9 months (varying from 4 years 6 months to 6 years 10 months), the patients were free of recurrences. The one patient on stage IV had extensive invasion of the abdominal wall, but still recovered completely. One patient on stage III underwent combined chemotherapy and hyperthermotherapy, but heating had obviously been insufficient. There was a residue of malignant cells after the treatment and we performed a penectomy. Regarding functional preservation of the penis a multidisciplinary therapy incorporating hyperthermotherapy can be expected to increase the curativity. This indicates that it could induce in an advanced case, where an operation would be difficult, complete remission.

KEYWORDS: penile cancer, hyperthermia, radiotherapy, chemotherapy

*PMID: 8379345 [PubMed - indexed for MEDLINE]

Copyright (C) OKAYAMA UNIVERSITY MEDICAL SCHOOL

Hyperthermotherapy Added to the Multidisciplinary Therapy for Penile Cancer

Masahiro Kuroda*, Tomoyasu Tsushima^a, Yasutomo Nasu^a, Junichi Asaumi, Koji Nishikawa, Xian Shu Gao, Ikuo Joja, Yoshihiro Takeda, Izumi Togami, Eiichi Makihata, Shoji Kawasaki^b, Hiroyuki Ohmori^a and Yoshio Hiraki

Department of Radiology, Okayama University Medical School, Okayama 700, ^aDepartment of Urology, Okayama University Medical School, Okayama 700, and ^bDepartment of Radiation Technology, School of Health Sciences, Okayama University, Okayama 700, Japan

We performed a long-term follow-up of 4 patients with penile cancer who underwent hyperthermotherapy from August 1985 until August 1992. Hyperthermia was applied using a frequency of 350 MHz with a waveguide applicator twice a week for 60 min each for an average of 9.5 times (varying from 6 to 13 times). The total heating time that the temperature of urethra could be kept above 42 °C, was 166 min on the average (ranging from 0 to 463 min). Two patients classified as stage I according to the Jackson classification and 1 patient classified as stage IV underwent combined radiotherapy and received an average radiation dose of 53 Gy (range, 40-70 Gy). Among these patients 2 underwent combined chemotherapy with bleomycin or peplomycin. Malignant cells disappeared posttherapeutically and in August 1992, after an average of 5 years and 9 months (varying from 4 years 6 months to 6 years 10 months), the patients were free of recurrences. The one patient on stage IV had extensive invasion of the abdominal wall, but still recovered completely. One patient on stage III underwent combined chemotherapy and hyperthermotherapy, but heating had obviously been insufficient. There was a residue of malignant cells after the treatment and we performed a penectomy. Regarding functional preservation of the penis a multidisciplinary therapy incorporating hyperthermotherapy can be expected to increase the curativity. This indicates that it could induce in an advanced case, where an operation would be difficult, complete remission.

Key words : penile cancer, hyperthermia, radiotherapy, chemotherapy

Treatment of penile cancer should be first curative, and should also try to maintain morphology and function of the penis under the given circumstances. Thus, patients classified as T1, 2 according to the TNM classification of UICC (International Union Against Cancer) (1), or as stage I or II according to the Jackson classification (2) are conservatively treated with radiotherapy and chemotherapy, and surgery is indicated in most advanced cases (3). There are only a few reports on hyperthermotherapy for penile cancer. To improve the curativity of conservative

therapy for penile cancer we added hyperthermotherapy to the multidisciplinary therapy for 4 patients with penile cancer. We then conducted a long-term follow-up and report our results here.

Subjects and Methods

Table 1 shows the patients included in the study. Site of the therapy was the penis in 3 patients and the invaded abdominal wall in 1 patient. The average age was 51 years (aged 38-66 years). The histologic type in all patients prior to the therapy was well differentiated squamous cell carcinoma. According to the Jackson

*To whom correspondence should be addressed.

Table 1 Clinical characteristics of patients

Cases	Age(year)	Conditions of penile cancer		
		Histology	Site	Jackson stage ^a (TNM stage ^b)
1	66	Well diff. sq. carcinoma	Prepuce	Stage I (T2N0M0)
2	38	Well diff. sq. carcinoma	Corona of glans	Stage I (T2N0M0)
3	46	Well diff. sq. carcinoma	Prepuce	Stage I (T2N0M0)
4	55	Well diff. sq. carcinoma	Corona of glans	Stage IV (T4N0M0)
			Loss of penis	Stage IV (T4N0M0)
			Invasion to scrotum and abdominal wall	Stage IV (T4N0M0)
			Prepuce	Stage III (T2N1M0)
			Shaft of penis	Stage III (T2N1M0)

a: Stage I, those confined to glans and/or prepuce; Stage IV, those with a primary tumour extending off the shaft of the penis; Stage III, those with malignant, but operable, groin nodes.

b: T2, those with invasion to corpus spongiosum penis; T4, those with invasion to other neighboring organs; N0, those without nodes metastasis; N1, those with a superficial inguinal node metastasis; M0, those without distant metastasis.

Abbreviations: sq., squamous cell; diff., differentiated.




Fig. 1 Heating of the penile lesion. The lesion was placed between the urethra and the waveguide applicator and the penis wrapped with a muscle tissue equivalent phantom. Bowman thermistor thermometers were placed on the superior surface (No. 1), into the urethra (No. 2) and on the inferior surface (No. 3) of the penis. Temperature of the applicator bolus was kept at 42°C and we tried to keep the temperature in the urethra above 42°C.

classification (2) there were 2 patients with stage I and 1 patient each with stage III and IV cancer.

Table 2 shows the therapies used. For the hyperthermotherapy we used the BSD-1000 waveguide applicator MA-150 working with 350 MHz made by BSD Medical Corporation (Utah, USA).

Hyperthermia was applied twice a week for 60 min each. Fig. 1 illustrates the hyperthermotherapy for the penile treatment sites. We attached the applicator so that the lesion was situated between it and the urethra, while the penis was wrapped with a muscle tissue equivalent phantom. Bowman thermistor thermometers were placed in the urethra, on top and under the penis. To heat the whole lesion to above 42°C, we tried to maintain a temperature of more than 42°C within the urethra. For the treatment of the abdominal wall invasion we inserted a thermometer into the lesion and tried to keep the temperature above 42°C. Three patients received an average radiation dose of 53 Gy (range, 40–70 Gy) in fractions of 2 Gy 5 times a week using ⁶⁰Co-γ ray emitted from a Toshiba RI-107. The hyperthermotherapy was performed immediately after the irradiation. All 3 patients underwent combined chemotherapy with bleomycin (Nipponkayaku Co., Ltd., Tokyo, Japan) or peplomycin (Nipponkayaku). We applied the anticancer agents simultaneously with the hyperthermotherapy as continuous subcutaneous infusion and ointment therapy. After these therapies we obtained biopsy specimens and evaluated the effectiveness.

Results

Hyperthermotherapy was given an average of 9.5 times (ranging from 6 to 13 times) (Table 2). During each session transient pain developed in the heated area depending on the hyperthermic output. For this reason, the total heating time that the temperature could be kept above 42°C, varied widely among the patients and was 166 min on the average (ranging from 0 to 463 min). Heating was

Table 2 Treatment methods

Cases	Hyperthermotherapy			Combined therapy	
	Number of heating	Total heating time over 42°C (min)	Average heating score ^a	Radiotherapy	Chemotherapy
1	6	170	5.8	⁶⁰ Co γ-ray 70Gy (TDF 109.4)	Peplomycin c.s.i. Total 145mg
2	10	29	3.2	⁶⁰ Co γ-ray 50Gy (TDF 80.6)	—
3	13	463	6.9	⁶⁰ Co γ-ray 40Gy (TDF 61.9)	Bleomycin o.t. Peplomycin c.s.i. Total 300mg
4	9	0	1.4	—	Bleomycin o.t. Bleomycin c.s.i. Total 265mg

^a: According to the classification of Nakada *et al.* (Reference (4))

Abbreviations: Gy, gray; TDF, time, dose and fractionation; c.s.i., continuous subcutaneous infusion; o.t., ointment therapy

Table 3 Results of the treatments

Cases	Histology after treatments	Effect	Observation after treatments ^a
1	Sq. hyperplasia No malignant cells	CR	Alive (6 yrs 10 months) Without recurrence
2	No malignant cells	CR	Alive (4 yrs 6 months) Without recurrence
3	No malignant cells	CR	Alive (6 yrs) Without recurrence Skin graft (after 8 months)
4	Existence of malignant cells	NC	Dead (2 yrs 8 months) Partial penectomy (after 0.5 month) Local recurrence (after 11 months)

^a: Observation until August 1992

Abbreviations: Sq., Squamous cell; CR, complete response; NC, no change; yrs, years




Fig. 2 Case No. 1. A: Before treatment. B: After treatment. Tumor size decreased after the therapy.

insufficient in case No. 4. The average heating score according to the classification of Nakada *et al.* (4), as one index of heating patterns, was 4.3 on the average (ranging from 1.4 to 6.9).

Table 3 shows the therapeutic results. In 2 patients classified as stage I and 1 patient classified as stage IV according to the Jackson classification, malignant cells disappeared due to the combined radiotherapy, which

qualified a complete response (CR). The patients were free of recurrences until August 1992, after an average of 5 years and 9 months (varying from 4 years 6 months to 6 years 10 months). Neither during the therapy nor during the follow-up were there any side-effects that required treatment.

Fig. 2 shows case No. 1. Tumor size decreased and malignant cells disappeared posttherapeutically (Fig. 3).




Fig. 3 Photomicrograph of the biopsy specimen from case No. 1. (H-E staining $\times 100$) A: Before treatment. Well differentiated squamous cell carcinoma. B: After treatment. Malignant cells have disappeared and the sample shows only squamous cell hyperplasia.



Fig. 4 Case No. 3. A: Before treatment. The penis was lost spontaneously and the tumor invasion extended up to the lower abdominal wall. B: After treatment. The lesion discolored yellowish-white and malignant cells disappeared. A catheter is inserted transcutaneously into the bladder. C: Eleven months after the therapy. Eight months after the therapy we performed a skin graft. D: Six years later. We observed no recurrence.

was evaluated as no change (NC) and half a month later we performed a partial penectomy.

Discussion

Penile cancer is a comparatively rare disease among genitourinary diseases in men. The clinical statistics on inpatients and outpatients in the Department of Urology, Okayama University Medical School (5, 6) showed that there were on the average only 2.5 patients among 1,603 male outpatients per year from 1,980 until 1,990. Thus, regarding its therapy most reports are retrospectively summarized case reports. Multifacility joint studies are required to establish an effective multidisciplinary therapy (7).

Hyperthermia is an obstacle to the sublethal damage repair following irradiation (8). Hypoxic cells at low pH (9) or cells in S-phase of the cell cycle (10) are rather resistant to radiation, but highly susceptible to hyperthermia. This is the reason for the effectiveness of combined hyperthermotherapy and radiotherapy. Hyperthermia enhances the action of bleomycin and peplomycin (11). Bleomycin also enhances the action of the radiation (12). Thus, mutual enhancement of the respective action can be expected from a combination of radiation, hyperthermia and bleomycin or peplomycin. To permit simultaneous use of hyperthermia and radiation and to reduce side-effects on the lung (13, 14) bleomycin or peplomycin are applied as continuous subcutaneous infusion or as ointment therapy.

To preserve morphology and function of the penis, patients on low stages are usually treated conservatively with radiotherapy and chemotherapy (3, 15-20). These therapies have brought the high curativity against the lesions. However, posttherapeutic recurrences sometimes occur (19, 20). For this reason some facilities choose surgery even on low stages. We achieved CR and observed no recurrences during a long-term follow-up in one patient each on stage I and IV with combined radiotherapy, chemotherapy and hyperthermotherapy and in one patient on stage I with combined radiotherapy and hyperthermotherapy. Combination with hyperthermotherapy could increase the curativity of the individual treatment forms. Moreover, it may lead to complete recovery even in advanced cases in which surgery would be difficult.

In the one patient with stage III cancer we administer-



Fig. 5 Computed tomogram of case No. 3. A: Before treatment. B: After treatment. The arrowhead points to the tumor. Posttherapeutically, tumor size decreased significantly.

Fig. 4 shows case No. 3. Prior to the treatment (Fig. 4A) the penis had lost spontaneity and a bright red tumor invasion extended up to the lower abdominal wall. Posttherapeutically (Fig. 4B) the lesion turned yellowish-white, shrank and malignant cells finally disappeared. A computed tomogram showed a significant decrease in tumor size (Fig. 5). After the treatment we performed a skin graft and did not observe any recurrence during the 6 years of follow-up (Fig. 4D).

The patient (case No. 4) with stage III cancer underwent combined hyperthermotherapy and chemotherapy with bleomycin. Because of insufficient heating some malignant cells remained after the therapy. This patient

ed combined chemotherapy and hyperthermotherapy with bleomycin. However, because we could not achieve sufficient hyperthermia, results were unsatisfactory. Hahn *et al.* (21) reported that bleomycin sensitivity increased *in vitro* significantly at 43°C, but at temperatures below 41°C there was almost no change. Thus, regarding combined use of bleomycin and hyperthermia one must first ascertain whether sufficient hyperthermia can be achieved and then continue with the therapy.

Although few case reports deal with hyperthermotherapy for penile cancer, no report deals its role in the therapeutic regimen among the plural patients within the scope of the author's survey. Obama *et al.* (22) reported complete remission in a patient with advanced penile cancer using hot packs and combined radiotherapy and chemotherapy. To achieve uniform heating of the lesion hyperthermia with electromagnetic waves is advantageous. In the present study we used a waveguide applicator, but in some patients the associated pain prevented the achievement of sufficient hyperthermia. We consider investigations of alternative methods of heating the penile lesion, including intraluminal and capacitive heating, as an important task.

Acknowledgments. The contents of this article were presented at the ninth Annual Meeting of the Japanese Society of Hyperthermic Oncology held on September 10–11, 1992. This work was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Education, Science and Culture of Japan (63010052, 01010026, 02151022, 03857136). I would like to express my gratitude to the doctors of the Department of Urology, Okayama University Medical School for their support throughout this study.

References

1. UICC (International Union Against Cancer): Penis; in TNM Classification of Malignant Tumours, 4th edition, Springer-Verlag, Berlin, Heidelberg, New York, London, Paris, Tokyo (1987) pp 130–132.
2. Jackson SM: The treatment of carcinoma of the penis. *Br J Surg* (1966) **53**, 33–35.
3. Kawai T and Tsuya A: Penile cancer; in Encyclopedia of Clinical Radiology Vol. 33, Tasaka ed, Nakayama-Shoten Co., Ltd., Tokyo (1985) pp 39–45 (in Japanese).
4. Nakada Y, Matsuda T and Sugiyama A: Analysis of human body heating using thermotron; in Hyperthermic Oncology, Matsuda and Kikuchi eds, The Japanese Society of Hyperthermic Oncology, Tokyo (1984) pp 148–149.
5. Ohmori H, Matsumura Y, Kumon H, Tsushima T, Tsugawa M, Oeda T, Kobashi K, Yoshida M, Kaku S and Takenaka T: Clinical statistics on inpatients in the Department of Urology, Okayama University Medical School during an eleven-year period from 1980 to 1990. *Nishinohon J Urol* (1992) **54**, 517–521 (in Japanese).
6. Ohmori H, Matsumura Y, Kumon H, Tsushima T, Tsugawa M, Oheda T, Nishimura M, Uno S, Arata R and Takamatsu M: Clinical statistics on outpatients in the Department of Urology, Okayama University Medical School during an eleven-year period from 1980 to 1990. *Nishinohon J Urol* (1992) **54**, 512–516 (in Japanese).
7. Jones WG, Fossa SD, Hamers H and Van Den Bogaert W: Penis cancer: A review by the joint radiotherapy committee of the European Organisation for Research and Treatment of Cancer (EORTC) genitourinary and radiotherapy groups. *J Surg Oncol* (1989) **40**, 227–231.
8. Ben-Hur E, Elkind MM and Bronk BV: Thermally enhanced radiosensitivity of cultured Chinese hamster cells: Inhibition of repair of sublethal damage and enhancement of lethal damage. *Radiat Res* (1974) **58**, 35–51.
9. Gerweck LE, Jennings M and Richards B: Influence of pH on the response of cells to single and split doses of hyperthermia. *Cancer Res* (1980) **40**, 4019–4024.
10. Gerweck LE, Gillette EL and Dewey WC: Effect of heat and radiation on synchronous Chinese hamster cells: Killing and repair. *Radiat Res* (1975) **64**, 611–623.
11. Neumann HA, Herrmann DB, Fiebig HH and Engelhardt R: Treatment of human clonogenic tumor cells and bone marrow progenitor cells with bleomycin and peplomycin under 40.5 degrees C hyperthermia *in vitro*. *Eur J Cancer Clin Oncol* (1989) **25**, 99–104.
12. Terasima T, Takabe Y and Yasukawa M: Combined effect of X-ray and bleomycin on cultured mammalian cells. *Gann* (1975) **66**, 701–703.
13. Miyamoto T: Antitumor effects and pulmonary toxicity of bleomycin administered by continuous subcutaneous infusion in patients with advanced cervical cancer. *Jpn J Cancer Chemother* (1987) **14**, 1830–1835 (in Japanese).
14. Satake I, Tari K, Honma T, Noguchi Y and Yoshida K: Decreased pulmonary toxicity of peplomycin in elderly patients employing continuous subcutaneous infusion. *J Jpn Soc Cancer Ther* (1985) **20**, 1349–1356 (in Japanese).
15. Uchida T, Sanjyo Y, Omata T, Fujino A, Yoshizawa K, Mashimo S, Endo T, Ishibashi A and Koshiba K: Clinical study of 16 cases of penile cancer. *Nishinohon J Urol* (1992) **54**, 324–327 (in Japanese).
16. Dokita S, Someno T, Takahashi T and Amino Y: Carcinoma of the penis: Experience at the Mito National Hospital from 1968 to 1987. *Nishinohon J Urol* (1990) **52**, 1368–1372 (in Japanese).
17. Ogawa A, Tsuruta K, Hirayama H, Miyamoto J, Ueda S, Yamamoto T, Shimomura T, Takano S, Imafuji M, Morihisa K, Yano S, Hamada Y and Asayama Y: Clinical studies of 58 cases of penile cancer. *Nishinohon J Urol* (1990) **52**, 1712–1717 (in Japanese).
18. Miyao N, Kumamoto Y, Tsukamoto T, Ohmura K, Yamazaki K and Iwasawa M: Clinical study of penile cancer. *Jpn J Urol* (1990) **81**, 1550–1554 (in Japanese).
19. Harabayashi T, Nonomura K, Togashi M, Seki T and Koyanagi T: Clinical study of penile carcinoma in 38 cases. *Jpn J Urol* (1990) **81**, 1045–1050 (in Japanese).
20. Nakao H, Kawai T and Kaneda K: Clinical observation of carcinoma of the penis. *Jpn J Urol* (1976) **67**, 647–662 (in Japanese).
21. Hahn GM, Braun J and Har-Kedar I: Thermochemotherapy: Synergism between hyperthermia (42–43°) and adriamycin (or bleomycin) in mammalian cell inactivation. *Proc Natl Acad Sci USA* (1975) **72**, 937–940.
22. Obama T, Mitsuhashi N, Yoshimoto J, Matsumura Y and Ohmori H: Combination therapy with continuous infusion of peplomycin, radiation and hyperthermia in advanced penile cancer: A case report. *Nishinohon J Urol* (1981) **43**, 769–774 (in Japanese).

Received October 29, 1992; accepted December 22, 1992.

Therapeutic Effect of Neuraminidase-Treated LAK Cells on Liver Metastasis of Colon 26

Shingo Kamitani, Noriaki Tanaka*, Shigeru Yunoki, Akio Hizuta and Kunzo Orita

First Department of Surgery, Okayama University Medical School, Okayama 700, Japan

To improve the lymphokine-activated killer (LAK) cell therapy for liver metastasis, two methods which enhance accumulation of LAK cells in the liver were examined for their effects on the liver metastasis of Colon 26 cancer cells in BALB/c mice. Distribution of LAK cells in the mice was examined by the ^{51}Cr labeling method. Portal vein infusion of LAK cells or tail vein infusion of neuraminidase treated-LAK (N-LAK) cells showed an augmented accumulation of infused cells in the liver. In the first experiment, LAK cells (5×10^7 cells) were infused in the portal vein or tail vein at days 3 and 7 after the inoculation of 5×10^4 tumor cells and 1×10^4 units of IL-2 were given three times a day from day 3 to day 7. The portal infusion of LAK cells produced a greater reduction of liver metastases compared with the peripheral infusion. In the second experiment, 5×10^7 LAK cells or N-LAK cells were infused via the tail vein on days 1 and 3, and 1×10^4 units of IL-2 were given once a day from day 1 to day 5 after the inoculation of 1×10^4 tumor cells. The therapeutic effect of N-LAK cells was greater than non-treated LAK cells on the number of metastatic lesions and the survival time of mice. Since access to the human portal vein is difficult and risky in clinical situation, peripheral infusion of N-LAK cells is preferable.

Key words : LAK cell, neuraminidase, liver metastasis

Lymphokine-activated killer (LAK) cells are generated by cultures of normal lymphocytes with interleukin-2 (IL-2) without antigenic stimulation. They were first documented by Grimm *et al.* as activated lymphocytes having lytic activity for fresh, autologous and syngeneic cells, regardless of whether the tumor target cells were natural killer sensitive or resistant(1, 2). In animal models, transfer of LAK cells and IL-2 induced regression of pulmonary and hepatic metastasis (3). Large doses of IL-2 and LAK cells resulted in tumor regression in patients with certain advanced metastatic cancers, including renal cell carcinoma and melanoma. However, the therapeutic effects were limited to a minority of patients(4, 5), and considerable toxicity such as increase in capillary permeability accompanied the therapy (6).

Further enhancement of the therapeutic effects of

LAK cells requires study of the following two problems a) improvement of the accessibility to tumor tissues, and b) enhancement of the anti-tumor cytotoxicity. Motility is important for lymphocytes to infiltrate tumors or other inflammatory lesions. However, tumoricidal activity and motility of LAK cells are independently and sometimes inversely regulated (7). Intercellular adhesion is also important for the killing activity of lymphocytes. Neuraminidase treatment of lymphocytes increases the binding efficiency of lymphocyte subsets with endothelial cells (8). However, this treatment interferes with the normal distribution of lymphocytes in organisms, so that the majority do not home into lymphoid organs but are trapped in the liver (9). In this study, we have examined the effects of neuraminidase-treated LAK (N-LAK) cells on liver metastasis.

*To whom correspondence should be addressed.

Materials and Methods

Animals. Specific pathogen-free BALB/c mice between 6 and 7 weeks old, were obtained from the Shizuoka Experimental Animal Farm (Hamamatsu, Japan). Mice were housed in groups of 10 or less per cage, and fed an Oriental solid diet (Oriental Yeast Co., Tokyo, Japan).

Tumors. The Colon 26 (10), an undifferentiated colon adenocarcinoma generated from BALB/c mice injected with N-methyl-N-nitrosourea was cultured *in vitro* with RPMI 1640 containing 10 % fetal calf serum (FCS, Grand Island Biological Co., Grand Island, NY, USA). A single cell suspension of these cells, obtained by trypsin treatment, was injected at concentrations of 1×10^4 or 5×10^4 cells per BALB/c mouse body via the mesenteric vein under light ether anesthesia.

Preparation of LAK cells. Spleens were removed, cut finely in the medium, passed through a 150 mesh, and placed in 0.83 % NH_4Cl -Tris buffer to lyse erythrocytes, thus isolating lymphocytes. The lymphocytes were washed 3 times with Hanks balanced saline solution (HBSS) and resuspended in complete medium (CM), which was RPMI 1640 medium (Nissui Pharmaceutical Co., Tokyo, Japan) supplemented with 25mM N-2-hydroxyethyl piperazine-N-2 ethane sulfonic acid (Sigma Chemical Co., St. Louis, MO, USA), 2mM L-glutamine (Wako pure Chemical Industries, Ltd., Osaka, Japan), 50 μM 2-mercaptoethanol (Sigma Chemical Co., St. Louis, MO, USA), streptomycin (100 $\mu\text{g}/\text{ml}$), Penicillin G (100 units) and 10 % heat inactivated FCS. Lymphocytes were cultured at a concentration of 2.5×10^6 cells/ml in CM added with 1,000 units/ml of human recombinant IL-2 (Shionogi Pharmaceutical Co., Osaka, Japan) under 5 % CO_2 in air at 37 °C for 3 days.

Neuraminidase treatment of LAK cells. LAK cells were incubated at 5×10^7 cells/ml with various amounts (0.02-0.5 unit/ml) of neuraminidase (Behring Institute, Germany) at 37 °C for 30 min, and washed three times with HBSS. Cell viability, determined by Trypan-blue dye exclusion test, was not affected by this treatment.

Assay for the distribution of infused lymphocytes. Distribution of LAK cells was examined using normal mice without tumor inoculation. LAK cell suspension (5×10^7 cells) was added with 200 μCi of $\text{Na}_2^{51}\text{CrO}_4$ (New England Nuclear, Boston, MA, USA) and incubated at 37 °C for 1 h. The cells were then washed three times. Approximately 2×10^7 viable cells in 0.2 ml were transfused into the tail vein (peripheral infusion) or into the transposed spleen (portal infusion) of 3 mice under anesthesia with ether. Recipients were killed 24 h after injection, and the liver, lungs and spleen were removed. The radioactivity of each organ was expressed as a percentage of the total radioactivity of injected cells.

Cytotoxicity assay. Cytotoxic function was examined by ^{51}Cr -release assay. Colon 26 undifferentiated carcinoma cells (10), YAC-cells from a Molony virus-induced lymphoma in A/St mice (11), and JTC-11 cells from Ehrlich ascites tumor (12) were

labeled with radioactive chromium and used as target cells. Various numbers of effector cells were incubated with 1×10^4 ^{51}Cr -labeled target cells in 0.2 ml of CM in 96-well round-bottomed microtiter plates. The plates were centrifuged at 300 *g* for 5 min and incubated at 37 °C in a 5 % CO_2 for 12 h. After incubation, 0.1 ml of the supernatant was counted in a gamma counter. Cytotoxicity was calculated by the following formula:

$$\% \text{ specific lysis} = 100 \times \frac{\text{experimental cpm} - \text{spontaneous cpm}}{\text{total cpm} - \text{spontaneous cpm}}$$

Transposition of the spleen. Under general anesthesia by ether, each mouse was positioned in the right decubitus, and the skin was sterilized with chlorhexidine alcohol, and a 1 cm lateral incision was made in the left subcostal arch region. The spleen was transposed to the subcutaneous region, and the peritoneum and skin were closed, leaving the spleen attached by its vascular pedicle.

Experimental procedure. Protocol 1 (4 groups of 5 mice each) was designed to examine the effects of the portal infusion of LAK cells via the transposed spleen. All mice were inoculated with 5×10^4 Colon 26 cells via a mesenteric vein (day 0). LAK cells were injected at 5×10^7 cells into the portal vein through the transposed spleen or into the tail vein on days 3 and 7. IL-2 (1×10^4 units in 1 ml HBSS) was given intraperitoneally every 8 h for 5 days after the first transfusion of LAK cells. All were killed 14 days later, and liver metastases were assessed macroscopically. Whitish tumor nodules were mostly localized on the surface of the liver.

In protocol 2 (4 groups of 5 mice each), the effects of N-LAK cells were examined. LAK cells or N-LAK cells were injected at 5×10^7 via the tail vein on days 1 and 3. After inoculation of 1×10^4 tumor cells, IL-2 (1×10^4 units in 1 ml HBSS) was given intravenously once a day on days 1 through 5. One group of these mice was killed 21 days later, and the metastatic liver foci were examined. Another group of these mice was observed to measure their survival time.

Statistics. Statistical analysis was performed using Student's *t*-test.

Results

Lymphocyte distribution by portal and peripheral infusion. ^{51}Cr -labeled fresh lymphocytes and LAK cells were infused via the tail vein or portal vein, and the accumulation of radioactivity in the liver, spleen, and lungs was examined at 24 h after infusion. As shown in Table 1, LAK cells infused via the portal vein accumulated more in the liver than LAK cells infused via the tail vein. Fresh lymphocytes showed no changes in their distribution by the route of infusion (Table 1).

Effect of neuraminidase treatment on the cytotoxicity

of LAK cells. After the neuraminidase treatment, LAK cells were observed to be morphologically intact and unagglutinated. The cells also showed no significant changes in the cytotoxic activity against JTC-11 and YAC-1 cells by the treatment at different concentrations between 0.01 and 0.5 units/ml of neuraminidase. The cytotoxicity of LAK cells against Colon 26 was not significantly affected by incubation with 0.5 units/ml of neuraminidase (Fig. 1)

Effect of neuraminidase treatment on the distribution of lymphocytes examined in normal mice. Fresh lymphocytes and LAK cells were incubated with 0.5 units/ml of neuraminidase, labeled with ^{51}Cr , and trans-

fused intravenously into the normal mice in which tumor cells were not injected. The radioactivity examined at 24 h after infusion was mainly detected in the liver and spleen. The treatment of lymphocytes with neuraminidase had so altered their distribution *in vivo* that there was less radioactivity in the spleen and substantially more in the liver. Similar changes were observed in the distribution of LAK cells (Table 2).

Augmentation of therapeutic effect on liver metastasis by portal infusion of LAK cells. This experiment used protocol 1, and metastatic nodules were counted on day 14 for each group. The first group was infused with physiological saline solution via the tail vein, the second

Table 1 Effect of administration route of ^{51}Cr -labeled lymphocytes on accumulation of the radioactivity in tissues of recipients

Infused lymphocytes	Route of administration	Trapping rate(%) ^a		
		Lung	Liver	Spleen
Spleen cells	Tail vein	1.5 ± 0.1	28.2 ± 0.5	30.1 ± 1.8
Spleen cells	Portal vein	1.0 ± 0.2	23.8 ± 1.2	37.6 ± 1.2
LAK cells	Tail vein	3.0 ± 0.2	37.3 ± 3.1	32.3 ± 3.4
LAK cells	Portal vein	6.5 ± 1	45.3 ± 2.2	31.2 ± 2.6

^a : Radioactivity of each organ is presented by % of the total activity of injected cells, and values are the mean ± SD of three mice.

* $p < 0.01$ (student's *t* test)





Fig. 1 Effect of neuraminidase on cytotoxic activity of LAK cells. LAK: lymphokine-activated killer; N-LAK: neuraminidase treated-LAK.

Table 2 Effect of neuraminidase treatment of ^{51}Cr -labeled lymphocytes on the distribution of the radioactivity in tissues of recipients

Infused lymphocytes	Neuraminidase treatment	Trapping rate(%) ^a		
		Lung	Liver	Spleen
Spleen cells	—	0.64 ± 0.05	34.5 ± 0.4	29.4 ± 1.1
	+	0.70 ± 0.02	53.2 ± 2.2	13.5 ± 0.6
LAK cells	—	0.66 ± 0.01	29.1 ± 3.2	36.0 ± 0.3
	+	0.71 ± 0.02	55.7 ± 1.5	14.2 ± 0.5

^a : Values are mean ± SD of three mice. * $p < 0.01$ (Student's *t* test)

**Fig. 2** Effect of transfusion of neuraminidase-treated LAK cells on the survival rate of tumor inoculated mice. LAK, N-LAK: See Fig. 1.

with fresh spleen cells via the portal vein, the third with LAK cells combined with IL-2 via the tail vein, and the fourth with LAK cells combined with IL-2 via portal vein. There were no significant differences between the first two groups. The experimental group infused with LAK cells via the tail vein showed significantly fewer metastases than the control group ($p < 0.01$). Furthermore, the portal infusion of LAK cells led to markedly fewer metastatic nodules than the peripheral infusion ($p < 0.05$) (Table 3).

Augmentation of the therapeutic effect of LAK cells on liver metastasis by in vitro neuraminidase treatment. The experiment was conducted according to protocol 2. There was no detectable difference in the number of metastatic foci between the two groups infused with either physiological saline solution or fresh spleen cells.

Compared with the latter group, the group infused with LAK cells and IL-2 showed significant reduction in the number of metastases. Further, the group infused with N-LAK cells and IL-2 showed the greatest reduction of metastases in the three experimental groups, with 44 % fewer metastases than the control (Table 4).

Effect of LAK therapy on survival time of tumor bearing mice. Survival studies were carried out by protocol 2. The mean survival time of the group infused with fresh lymphocytes was 32.0 days. Compared with this group, the experimental group infused with LAK cells or N-LAK cells in combination with IL-2, showed a significantly longer survival time; 37.4 days for the former and 41.6 days for the latter. The significant difference ($p < 0.05$) between these two experimental groups indicat-

Table 3 Effect of transfusion route of LAK cells on liver metastasis

Group	Route	No. of surface tumor ^a nodules in livers
Saline	Tail vein	> 230
Spleen cells	Portal vein	225 ± 43
LAK cells	Tail vein	98 ± 23 *
LAK cells	Portal vein	24 ± 26 *

^a : Values are mean ± SD of 5 mice. LAK: Lymphokine activated killer.
* $p < 0.01$; ** $p < 0.05$

Table 4 Effect of transfusion of neuraminidase treated LAK cells on liver metastasis and survival time of tumor inoculated mice

Group	No. of surface tumor ^a nodules in livers	Survival times ^b (days)
Saline	76.2 ± 7.8	31.8 ± 3.8
Spleen cells	72.2 ± 7.9	32.0 ± 3.1
LAK cells	46.4 ± 6.8 *	37.4 ± 3.4 *
N-LAK cells	33.6 ± 4.3 **	41.6 ± 3.8 **

^a, ^b : Values are mean ± SD of 5 mice. LAK: Lymphokine activated killer; N-LAK: neuraminidase treated LAK.

* $p < 0.01$; ** $p < 0.05$

ed a therapeutic effect of N-LAK cells on liver metastasis (Fig. 2, Table 4).

Discussion

The efficacy of cancer therapy with LAK cells depends on their cytolytic potential against tumor cells and their localization in the tumor tissue. For the latter, lymphocytes infused into a tumor-bearing host must avoid being trapped in irrelevant capillary beds, extravasate at appropriate points, and penetrate into primary or metastatic tumor masses. The efficiency of adoptive immunotherapy depends in part upon the motility of infused lymphocytes (13). However, tumoricidal lymphocytes show low activity in spontaneous motility and in chemokinetic response to IFN- γ , showing that LAK cells may not be the best tumor infiltrators (7). The poor locomotion of tumoricidal cells is not simply due to their large size (14, 15). LAK cells are significantly less deformable than fresh NK cells and T cells (16). This increased rigidity combined with their large size may explain the

high retention of LAK cells in the lungs immediately after intravenous injection. Therefore, LAK cells should be locally infused toward the target organ having tumor metastases. In the present study, the portal infusion of LAK cells through the transposed spleen was an effective method for delivering lymphocyte to the liver. However, in the case of peripheral infusion, accumulation of LAK cells in the tumor site must be augmented by other methods; augmentation of the motility of lymphocytes, or making a tumor attract the lymphocytes. Concerning the latter method, Hosokawa *et al.* reported that combined anti-cancer chemotherapy using cyclophosphamide enhanced the accumulation of LAK cells in the tumor (17).

Surface properties of lymphocytes control their traffic and distribution in the body. Treatment with a crude glycosidase preparation (18), trypsin (19), or neuraminidase, prevents redistribution of the lymphocytes in the body. Many treated lymphocytes do not home into lymphoid organs but are trapped in the liver until normal membrane properties are recovered (20, 21). We also observed in this study that N-LAK cells were trapped more in the liver and less in the spleen. The liver was the only organ in which increased trapping was found. Neuraminidase-treated rat lymphocytes have been reported to adhere strongly to rat hepatocytes *in vitro* (22). Treatment of lymphocytes with the proteolytic enzyme or neuraminidase has been known to increase cell mediated cytotoxicity, antibody-dependent cytotoxicity (23) and NK activity (24). In the present study, cytotoxic activities of LAK cells were not augmented by neuraminidase treatment, but the infusion of N-LAK cells had a good therapeutic effect on liver metastasis. Some other mechanism may be involved in the effect. Since isolated hepatocytes are mitogens for desialyated T cells (25), accumulated T cells in the liver may be activated to produce any cytokine which may further induce killer cells. In conclusion, N-LAK cells may effectively suppress liver metastases by their enhanced accumulation in the liver.

References

1. Grimm EA, Mazumder A, Zhang HZ and Rosenberg SA : Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. *J Exp Med* (1982) **155**, 1823-1841.
2. Rosenstein M, Yron I, Kaufman Y and Rosenberg SA: Lymphokine-

- activated killer cells: Lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin-2. *Cancer Res* (1984) **44**, 1946-1953.
3. Shiloni E, Lafreniere R, Mule JJ, Schwarz SL and Rosenberg SA : Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice. *Cancer Res* (1986) **46**, 5633-5640.
 4. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Marston L, Inehan W, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG and White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. *N Engl J Med* (1987) **316**, 889-897.
 5. Schoof DD, Garmolini BA, Davidson DL, Massaro AF, Wilson RE and Eberlin TJ: Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells. *Cancer Res* (1988) **48**, 5007-5010.
 6. Rosenstein M, Ettighausen SE and Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. *J Immunol* (1986) **137**, 1735-1742.
 7. Ratner S and Heppner GH: Motility and tumoricidal activity of interleukin-2-stimulated lymphocytes. *Cancer Res* (1988) **48**, 3374-3380.
 8. Pardi R, Bender JR, Dettori C, Giannazza E and Engleman EG: Heterogeneous distribution and transmembrane signaling properties of lymphocyte function-associated antigen (LFA-1) in human lymphocyte subsets. *J Immunol* (1989) **143**, 3157-3166.
 9. Woodruff JJ and Gesner BM: The effect of neuraminidase on the fate of transfused lymphocytes. *J Exp Med* (1969) **129**, 551-567.
 10. Corbett TH, Griswold DP, Roberts BJ, Peckham JC and Schabel FH: Tumor induction relationship in involvement of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. *Cancer Res* (1975) **35**, 2434-2438.
 11. Sjögren HO and Hellström I: Production of polyoma specific transplantation antigenicity in Moloney leukemia cells. *Exp Cell Res* (1965) **40**, 208-215.
 12. Hamasaki M: On the properties of an established cell strain, JTC-11, from Ehrlich ascites tumor in tissue culture: 1. The characteristics of the standard strain. *Okayama-Igakkai-Zasshi* (1964) **76**, 1-11 (in Japanese).
 13. Ratner S and Heppner GH: Infiltration of transferred lymphocytes into murine mammary tumors: A locomotion-requiring process. *Proc Am Assoc Cancer Res* (1986) **27**, 362.
 14. Rolstad B, Herberman RB and Reynolds CW: Natural killer cell activity in the rat: V. The circulation patterns and tissue localization of peripheral blood large granular lymphocytes (LGL). *J Immunol* (1986) **136**, 2800-2808.
 15. Maghazachi AA, Herberman RB, Vujanovic NL and Hiserodt JC: *In vivo* distribution and tissue localization of highly purified rat lymphokine activated killer (LAK) cells. *Cell Immunol* (1988) **115**, 178-194.
 16. Sasaki A, Jain RK, Maghazachi AA, Goldfarb RH and Herberman RB: Low deformability of lymphokine-activated killer cells as possible determinant of *in vivo* distribution. *Cancer Res* (1989) **49**, 3742-3746.
 17. Hosokawa M and Sawamura Y: Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide. *Cancer Immunol Immunother* (1988) **26**, 250-256.
 18. Gesner BM and Ginsburg V: Effect of glycosidases on the fate of transfused lymphocytes. *Proc Natl Acad Sci USA* (1964) **52**, 750-755.
 19. Woodruff J and Gesner BM: Lymphocytes: Circulation altered by trypsin. *Science* (1968) **161**, 176-178.
 20. Freitas AA and de Sousa M: The role of cell interactions in the control of lymphocyte traffic. *Cell Immunol* (1976) **22**, 345.
 21. Woodruff JJ and Woodruff JF: Virus-induced alterations of lymphoid tissues IV: The effect of Newcastle disease virus on the fate of transfused thoracic duct lymphocytes. *Cell Immunol* (1974) **10**, 78-85.
 22. Kolb H, Kriese A, Kolb-Bachofen V and Kolb H-A: Possible mechanism of entrapment of neuraminidase-treated lymphocytes in the liver. *Cell Immunol* (1978) **40**, 457-462.
 23. Kedar E, Ortiz de Landazuri M and Fahey JL: Enzymatic enhancement of cell-mediated cytotoxicity and antibody-dependent cell cytotoxicity. *J Immunol* (1974) **112**, 26-36.
 24. Schulof RS, Fernandes G, Good RA and Gupta S: Neuraminidase treatment of human T lymphocyte's effect on Fc receptor phenotype and function. *Clin Exp Immunol* (1980) **40**, 611-619.
 25. Novogrodsky A and Ashwell G: Lymphocyte mitogenesis induced by a mammalian liver protein that specifically binds desialylated glycoproteins. *Proc Natl Acad Sci USA* (1977) **74**, 676-678.

Received November 27, 1992; accepted March 15, 1993.